Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Go back to Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.54 +0.10 (2.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.44 | 52 Week High | $0.04 | |||
| Open | $4.38 | 52 Week Low | $0.00 | |||
| Day High | $4.67 | P/E | N/A | |||
| Day Low | $4.38 | EPS | $-0.09 | |||
| Volume | 936,172 | |||||
